Abstract：
In the present narrative review, we discuss the characteristics and differences between the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines in terms on their recommendations/suggestions for the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii infections.
Treatment of severe infections caused by nonfermenting gram-negative bacteria (NF-GNB) is posing both novel hopes and novel challenges to physicians worldwide, and both the IDSA and the ESCMID have recently updated/released their guidelines or guidance documents, based on different philosophies and providing recommendations for the treatment of NF-GNB infections. In order to correctly exploit recent advances in the treatment of such infections, IDSA and ESCMID approaches should be viewed as complementary and evolving, and should not preclude further revision based on accumulating evidence on the use of novel β-lactams and β-lactam/β-lactamase inhibitor combinations.
A joint consideration of both philosophies should leave the door opened for the wise use of novel agents, ultimately building precious experience on their use that could favorably influence future guidelines revisions.
Treatment of severe infections caused by nonfermenting gram-negative bacteria (NF-GNB) is posing both novel hopes and novel challenges to physicians worldwide, and both the IDSA and the ESCMID have recently updated/released their guidelines or guidance documents, based on different philosophies and providing recommendations for the treatment of NF-GNB infections. In order to correctly exploit recent advances in the treatment of such infections, IDSA and ESCMID approaches should be viewed as complementary and evolving, and should not preclude further revision based on accumulating evidence on the use of novel β-lactams and β-lactam/β-lactamase inhibitor combinations.
A joint consideration of both philosophies should leave the door opened for the wise use of novel agents, ultimately building precious experience on their use that could favorably influence future guidelines revisions.
摘要：
目的：在本叙述性综述中，我们讨论了美国传染病学会(IDSA)和欧洲临床微生物学和传染病学会(ESCMID)指南在铜绿假单胞菌和鲍曼不动杆菌感染治疗方面的特点和差异.
结果：治疗由非发酵革兰阴性菌（NF-GNB）引起的严重感染给全世界的医生带来了新的希望和新的挑战。IDSA和ESCMID最近都更新/发布了其准则或指导文件，基于不同的理念，并为NF-GNB感染的治疗提供建议。为了正确利用治疗此类感染的最新进展，IDSA和ESCMID方法应被视为互补和不断发展的方法，并且不应排除基于使用新型β-内酰胺和β-内酰胺/β-内酰胺酶抑制剂组合的证据的进一步修订。
结论：对两种哲学的共同考虑应该为明智使用新型药物打开大门，最终在它们的使用上建立宝贵的经验，这可能会有利地影响未来的指导方针修订。
结果：治疗由非发酵革兰阴性菌（NF-GNB）引起的严重感染给全世界的医生带来了新的希望和新的挑战。IDSA和ESCMID最近都更新/发布了其准则或指导文件，基于不同的理念，并为NF-GNB感染的治疗提供建议。为了正确利用治疗此类感染的最新进展，IDSA和ESCMID方法应被视为互补和不断发展的方法，并且不应排除基于使用新型β-内酰胺和β-内酰胺/β-内酰胺酶抑制剂组合的证据的进一步修订。
结论：对两种哲学的共同考虑应该为明智使用新型药物打开大门，最终在它们的使用上建立宝贵的经验，这可能会有利地影响未来的指导方针修订。
